Skip to main content
. 2005 Jun 25;47(4):230–239. doi: 10.1016/j.pcad.2005.01.001

Table 3.

Ongoing Clinical Trials

Trial Population Size Follow-up Regimen (vs Placebo) End Points
ACES46 Stable CAD patients 4000 4 y Azithromycin 600 mg every wk × 1 y Composite CV events
MARBLE Patients awaiting CABG 1200 – Azithromycin Composite CV events
PROVE-IT46 Acute coronary syndrome 4000 2 y Gatifloxacin ± statin Composite CV events
ANTIBIO Acute MI 872 – Roxithromycin Composite CV events

CABG indicates coronary artery bypass graft; ACES, Azithromycin and Coronary Events; MARBLW, Might Azithromycin Reduce Bypass List Events; PROVE-IT, Pravastatin or Atorvastatin Evaluation and Infection Therapy; ANTIBIO, Antibiotic Therapy After Acute Myocardial Infarction.